About 200 patients in Uganda began in October of last year a trial of a World Health Organization-approved injection containing the drugs cabotegravir, or CAB-LA, and rilpivirine. Results are due in 2024.
The treatment, developed by British drug maker GlaxoSmithKline is the first non-pill option against HIV, and studies have shown it even outperforms the efficacy of oral pills.
#voaafrica
6 сен 2024
